NASDAQ$UTHR
United Therapeutics Corp · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
United Therapeutics experienced revenue growth driven by Tyvaso, Orenitram, and Unituxin, with a significant increase in net income compared to the previous year.
United Therapeutics reported a 22% increase in total revenue to $461.9 million for the first quarter of 2022, compared to $379.1 million in the first quarter of 2021. Net income saw a substantial rise to $239.9 million, a 748% increase from $28.3 million in the same period last year. The company is progressing with its phase 3 studies and anticipates potential FDA approval for Tyvaso DPI.
- Total revenue increased by 22% year-over-year, reaching $461.9 million.
- Net income increased significantly to $239.9 million, up 748% from the previous year.
- Tyvaso revenue grew by 40% due to increased quantities sold and label expansion.
- The company is actively progressing seven phase 3 studies and awaiting the FDA's decision on Tyvaso DPI.
Headline financials
Revenue & EPS history
United Therapeutics · Revenue · Quarterly
$462M
Revenue by segment
United Therapeutics · $462M total across 6 segments · Q1 2022
- Nebulized Tyvaso$172M+39.8%37.2%
- Remodulin$132M+1.2%28.5%
- Orenitram$82.8M+14.4%17.9%
- Unituxin$55.6M+26.7%12.0%
- Other$10M—2.2%
- Adcirca$9.8M+2.1%2.1%
Forward guidance
United Therapeutics did not provide specific forward guidance in this report, but highlighted their goals of reaching 6,000 U.S. patients on Tyvaso by the end of 2022 and 25,000 patients on their therapies by the end of 2025.
Tailwinds
- Continued traction for Tyvaso in pulmonary hypertension associated with interstitial lung disease.
- Awaiting the FDA’s decision on Tyvaso DPI.
- Working toward reaching 6,000 patients on Tyvaso therapy by the end of 2022.
- Working toward reaching 25,000 patients on our therapies by the end of 2025.
- Progressing seven phase 3 studies.
Headwinds
- FDA issued a complete response letter (CRL) from the FDA noting a single deficiency preventing approval of Tyvaso DPI, related to an open inspection issue at a third-party facility.
- The FDA had not yet completed its review of a Citizen Petition submitted to the FDA in July 2021 concerning the safety of an excipient in Tyvaso DPI.
- The FDA requested additional information concerning the pulmonary safety of Tyvaso DPI related to the Citizen's Petition.
- Decrease in U.S. Remodulin revenues was primarily due to a decrease in quantities sold.
- Increase in legal expenses related to litigation matters
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
+0.6%
Avg return
Earnings day
+0.2%
Avg return
5 days after
+1.1%
Avg return
30 days after
57%
39 / 68 earnings
Positive
+16.2%
Q3 2022
Best reaction
-13.0%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.3% | -0.4% | -4.0% | |
| Q4 2025 | +13.1% | +8.5% | +10.4% | |
| Q3 2025 | +9.7% | +5.6% | +17.0% | |
| Q1 2025 | +0.8% | -0.7% | +6.0% | |
| Q4 2024 | -10.8% | -13.3% | -14.1% | |
| Q3 2024 | +6.0% | +6.8% | +5.0% | |
| Q2 2024 | -2.9% | -3.5% | +7.7% | |
| Q1 2024 | +10.2% | +11.2% | +17.4% | |
| Q4 2023 | +1.6% | +4.4% | +11.1% | |
| Q3 2023 | +2.4% | +2.4% | +8.0% | |
| Q2 2023 | -3.4% | -1.0% | -5.0% | |
| Q1 2023 | -5.7% | -8.0% | -5.1% | |
| Q4 2022 | -2.7% | -3.3% | -13.8% | |
| Q3 2022 | +16.2% | +16.8% | +22.0% | |
| Q2 2022 | -1.5% | -2.7% | -0.8% | |
| Q1 2022 | +4.1% | -0.6% | +27.2% | |
| Q4 2021 | -13.0% | -14.0% | -9.5% | |
| Q3 2021 | +4.8% | +5.1% | -3.2% | |
| Q2 2021 | +13.7% | +15.0% | +16.7% | |
| Q1 2021 | -1.7% | -2.8% | -9.9% | |
| Q4 2020 | -2.1% | -0.6% | -0.7% | |
| Q3 2020 | +5.6% | +8.6% | +9.8% | |
| Q2 2020 | +0.3% | +2.9% | -6.3% | |
| Q1 2020 | -0.2% | +2.0% | +7.5% | |
| Q4 2019 | -10.7% | -8.0% | -19.1% | |
| Q3 2019 | +3.3% | +3.6% | +6.1% | |
| Q2 2019 | +4.5% | -0.5% | +3.8% | |
| Q1 2019 | -1.3% | -1.9% | -18.1% | |
| Q4 2018 | +3.6% | -1.5% | -3.8% | |
| Q3 2018 | -6.2% | -6.2% | -3.7% | |
| Q2 2018 | +0.3% | +0.7% | +0.1% | |
| Q1 2018 | -8.3% | -8.3% | -4.2% | |
| Q4 2017 | -12.9% | -14.1% | -20.4% | |
| Q3 2017 | +0.2% | +0.8% | +5.1% | |
| Q2 2017 | -2.3% | -2.6% | -2.2% | |
| Q1 2017 | -1.0% | +1.0% | -2.2% | |
| Q4 2016 | -12.2% | -9.2% | -16.6% | |
| Q3 2016 | +4.5% | +6.0% | +19.0% | |
| Q2 2016 | +6.9% | +11.2% | +7.6% | |
| Q1 2016 | -10.6% | — | — | |
| Q4 2015 | -4.2% | — | — | |
| Q3 2015 | +8.8% | — | — | |
| Q2 2015 | +0.8% | — | — | |
| Q1 2015 | -4.4% | — | — | |
| Q4 2014 | +2.3% | — | — | |
| Q3 2014 | -1.9% | — | — | |
| Q2 2014 | +2.7% | — | — | |
| Q1 2014 | +12.4% | — | — | |
| Q4 2013 | -4.1% | — | — | |
| Q3 2013 | +3.8% | — | — | |
| Q2 2013 | +2.7% | — | — | |
| Q1 2013 | -1.6% | — | — | |
| Q4 2012 | +2.7% | — | — | |
| Q3 2012 | +2.9% | — | — | |
| Q2 2012 | +8.3% | — | — | |
| Q1 2012 | +0.8% | — | — | |
| Q4 2011 | -0.9% | — | — | |
| Q3 2011 | +8.0% | — | — | |
| Q2 2011 | +5.0% | — | — | |
| Q1 2010 | -5.3% | — | — | |
| Q1 2011 | +0.8% | — | — | |
| Q4 2008 | +1.8% | — | — | |
| Q4 2010 | +1.8% | — | — | |
| Q3 2009 | +8.0% | — | — | |
| Q3 2010 | +8.0% | — | — | |
| Q4 2009 | -8.2% | — | — | |
| Q2 2010 | -8.2% | — | — | |
| Q2 2009 | -8.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro